BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former senior official of the Bank of Japan predicts that a rate hike in October is "a real possibility," with a very low probability of postponement until next year
A former executive director in charge of monetary policy at the Bank of Japan stated that the Bank of Japan may raise its benchmark interest rate for the second consecutive month at the October policy meeting, which would be earlier than most economists expect.
Falling Oil Could Trigger a 10% Stock Market Rally, Says Wall Street Strategist
Bitcoin falls below $84,000, down 0.32% in 24 hours.
Retail investors exit, institutions take over! Amid the US Treasury storm, "smart money" moves in instead of withdrawing: $18.4 billions in options capital flows into US stocks, AI remains the top choice.
The latest data shows that institutional investors are taking over as the main drivers of the US stock market.
Crypto prices
More
